Pfizer-Wyeth M&a Analysis
|[pic][pic] |
|Pfizer-Wyeth Merger Analysis |
| |
|“Creation of the World’s Premier Biopharmaceuticals Company” |
| |
| |
| |
| |
| |
| |
| |
Executive Summary:
Pfizer-Wyeth Merger Deal Overview:
On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to
|Pfizer-Wyeth Merger Analysis |
| |
|“Creation of the World’s Premier Biopharmaceuticals Company” |
| |
| |
| |
| |
| |
| |
| |
Executive Summary:
Pfizer-Wyeth Merger Deal Overview:
On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to
References: 1) BMO Capital Markets Large-Cap Pharmaceuticals Report, January 2009 2) Credit Suisse US Major Pharmaceuticals Report, January 2009 3) Credit Suisse Pfizer and Wyeth Acquisition Report, February 2009 4) Pfizer-Wyeth Proxy Report, June 2009 5) www.Pfizer.com 6) WRDS Data Base 7) S&P Net Advantage Database